HIV cure
cure of HIV infection
HIV-associated cancer
Target HIV-associated Malignancies
Phase
HIV-infected individuals
value of VS2
innovative drug VS2
viral infection
Viral Reservoir ViroStatics
functional cure
ART-free remissions
Cyclin-Dependent Kinase Inhibitor VS2
long periods of ART
FIM study
ViroStatics strategy
similar drug
Pharma Customer
recent success of Hepatitis C cure
Health Systems
dependent tumors
Investigational New Drug application
apoptosis of infected cells
unique anti-CDK4
extensive use of systems biology
established pathway of oncology drugs
quality of life improvement
effects
patients
targets
indirect cause
capital
final users
cost savings
clonal expansion
good exposure
models
biotechnology industry
TRL6
potential
franchise
anticancer activity
SME instrument
sides
underlying pathogenetic problem
Euro market opportunity
tolerability profiles
Development
available antiretroviral therapy
advantages
indication
experienced management
GMP lot